Abstract 25I-NBOMe, a new psychoactive substance, is a potent 5-HT 2A receptor agonist with strong hallucinogenic potential. Recently, it was involved in several fatal and nonfatal intoxication cases. The aim of the present work was to study its phase I and II metabolism and its detectability in urine screening approaches. After application of 25I-NBOMe to male Wistar rats, urine was collected over 24 h. The phase I and II metabolites were identified by LC-HR-MS/ MS in urine after suitable workup. For the detectability studies, standard urine screening approaches (SUSA) by GC-MS, LC-MS n , and LC-HR-MS/MS were applied to rat and also to authentic human urine samples submitted for toxicological analysis. Finally, an initial CYP activity screening was performed to identify CYP isoenzymes involved in the major metabolic steps. 25I-NBOMe was mainly metabolized by O-demethylation, O,O-bis-demethylation, hydroxylation, and combinations of these reactions as well as by glucuronidation and sulfation of the main phase I metabolites. All in all, 68 metabolites could be identified. Intake of 25I-NBOMe was detectable mainly via its metabolites by both LC-MS approaches, but not by the GC-MS SUSA. Initial CYP activity screening revealed the involvement of CYP1A2 and CYP3A4 in hydroxylation and CYP2C9 and CYP2C19 in O-demethylation. The presented study demonstrated that 25I-NBOMe was extensively metabolized and could be detected only by the LC-MS screening approaches. Since CYP2C9 and CYP3A4 are involved in initial metabolic steps, drug-drug interactions might occur in certain constellations.
Introduction
In recent years, with N-2-methoxybenzyl phenethylamine (NBOMe) derivatives, a new class of the so-called new psychoactive substances (NPS) appeared on the drug scene. They are derived from a class of the well-known potent hallucinogenic phenethylamines, the so-called 2Cs [1] . The NBOMe derivatives are very potent serotonin receptor agonists as figured out in structure-activity relationship studies [2, 3] . Thus, they have a high potential for hallucinogenic effects with the risk of serotonergic toxicity. Among others, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe, 2C-B-NBOMe), 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe, 2C-C-NBOMe), and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe, 2C-I-NBOMe) have been sold and consumed as so-called research chemicals. For example, 25I-NBOMe is usually consumed in the form of blotter papers, powder, or as nose sprays at very low doses of 0.5-1.5 mg (https://www. erowid.org). In the meantime, most of them have been scheduled in many countries considering the common use and partly fatal poisoning cases [4] [5] [6] [7] [8] [9] . In such cases, the drugs must be screened and quantified in clinical and forensic laboratories. Several procedures for quantification of NBOMe's in serum specimen have been published [4, 10] , but if the consumed drugs are unknown, screening procedures, mostly in urine, are initially applied. One requisite for developing screening approaches reliably detecting such lipophilic drugs is to know the analytical targets in body samples [11] [12] [13] . Thus, the metabolism should be studied first. This is also relevant for assessing of drug-drug interactions or toxic risks. Such studies have been comprehensively performed for the underlying 2C analogues [14] [15] [16] [17] [18] [19] [20] [21] . However, there is no systematic study available on the metabolism or detectability in urine of NBOMe derivatives. Among the NBOMe derivatives, 25I-NBOMe seems to be the most commonly used drug. Stellpflug et al. [7] described the possible presence of three O-demethyl-isomers, but no detailed metabolism studies were done. Therefore, the aim of the present study was to elucidate the metabolism of 25I-NBOMe in rats and humans using Orbitrap (OT)-based LC-HR-MS/MS. Furthermore, the detectability of 25I-NBOMe and its metabolites by the authors' standard urine screening approaches (SUSA) by GC-MS [22] , LC-MS n [23] , or LC-HR-MS/MS (Helfer et al., submitted) should be studied.
10 mM aqueous ammonium formate buffer (pH 3) and acetonitrile (1:1, v/v) and 10 μL injected onto the LC-HR-MS/MS system.
Microsomal incubations for initial CYP activity screening studies
According to standard procedures [24, 25] , microsomal incubations were performed at 37°C at a concentration of 25 μM 25I-NBOMe with the CYP isoenzymes (75 pmol/mL, each) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5 for 30 min as well as HLM (20 mg protein/mL) as positive control. Besides enzymes and substrates, the incubation mixtures (final volume, 50 μL) contained 90 mM phosphate buffer (pH 7.4), 5 mM Mg 2+ , 5 mM isocitrate, 1.2 mM NADP + , 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. For incubations with CYP2A6 or CYP2C9, phosphate buffer was replaced with 45 and 90 mM Tris buffer, respectively, according to the Gentest manual. Reactions were initiated by addition of the microsomes and stopped with 50 μL of ice-cold acetonitrile, containing 5 μM trimipramine-d 3 as internal standard. The solution was centrifuged for 2 min at 14,000×g; 70 μL of the supernatant phase was transferred to an autosampler vial and 10 μL injected onto the LC-HR-MS/MS system.
LC-HR-MS/MS apparatus for identification of phase I and II metabolites and CYP initial screening
According to published procedures [26] , the extracts were analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) Accela LC system consisting of a degasser, a quaternary pump, and an HTC PAL Autosampler (CTC Analytics AG, Zwingen, Switzerland) coupled to a TF Q-Exactive system equipped with a heated electrospray ionization (HESI)-II source. The instrument was used in positive ionization mode or in positive/negative switching mode. Mass calibration was done prior to analysis according to the manufacturer's recommendations using external mass calibration.
Gradient elution was performed on a TF Accucore PhenylHexyl column (100 mm × 2.1 mm, 2.6 μm). The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1 %, v/v) and acetonitrile (1 %, v/v) (pH 3, eluent A) and ammonium formate solution with acetonitrile/methanol (50:50, v/v) containing formic acid (0.1 %, v/v) and water (1 %, v/v) (eluent B). The gradient and flow rate were programmed as follows: 0-1 min hold 1 % B, 1-16 min 5 % B to 95 % B, 16-18 min hold 95 % B, and 18-20 min hold 1 % B, constantly at 500 μL/min.
The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray voltage, 3.00 (positive polarity) and −4.00 kV (negative polarity); heater temperature, 320°C; ion transfer capillary temperature, 320°C; and S-lens RF level, 60.0. Mass spectrometry was performed in positive polarity mode for the eluate B and in positive/negative polarity switch mode for the eluate A using full scan (FS) data and a subsequent data dependent acquisition (DDA) mode with an inclusion list on the masses of the metabolites.
The settings for FS data acquisition were as follows: resolution, 35,000; microscans, 1; automatic gain control (AGC) target, 1e6; maximum injection time (IT), 120 ms; and scan range, m/z 70-1000. The settings for the DDA mode (loop count 5) with an inclusion list for the expected metabolites were as follows: precursor ions, transferred to an exclusion list for 1 s (dynamic exclusion); resolution, 17,500; microscans, 1; AGC target, 2e5; maximum IT, 250 ms; isolation window, 1.0m/z; HCD with stepped normalized collision energy (NCE), 17.5, 35, and 52.5 %; spectrum data type, profile; and underfill ratio, 0.1 %.
For analyzing the initial CYP activity screening, the MS settings and the mobile phases were the same. The inclusion list only contained the masses of corresponding metabolites (m/z 308.0148, 414.0561, and 444.0666). The gradient and flow rate were as follows: 0-0.5 min hold 20 % B, 0.5-2.5 min 20 % B to 50 % B, 2.5-4 min hold 50 % B, 4-5.5 min 50 % B to 80 %, 5.5-6 min hold 80 % B, and 6-7 min hold 20 % B, constantly at 500 μl/min.
GC-MS SUSA
The GC-MS SUSA was performed as described elsewhere [22] .
LC-MS
n SUSA
In accordance to Wissenbach et al. [23, 27] , the urine samples (100 μL) were worked up by precipitation as described for the identification of phase II metabolites. The samples were separated and analyzed using a TF LXQ linear ion trap MS equipped with a HESI II source and coupled to a TF Accela LC system consisting of a degasser, a quaternary pump, and an autosampler. Gradient elution was performed using a TF Hypersil Gold (150 × 2.1 mm, 1.9 μm) column and 10 mM aqueous ammonium formate buffer containing formic acid (0.1 %, v/v) as mobile phase A and acetonitrile containing formic acid (0.1 %, v/v) as mobile phase B. The gradient and flow rate were programmed from 98 to 0 % A at 500 μL/min within 21 min (injection volume 10 μL). DDA was conducted on precursor ions selected from MS . TF ToxID 2.1.1 was used for automatic target screening in the MS 2 screening mode. The settings were as follows: retention time (RT) window, 20 min; RT, 0.1 min; signal threshold, 100 counts; search index, 600; reverse search index, 700. ToxID was run automatically after file acquisition using an Xcalibur processing method starting both software tools [28] . The MS 2 and MS 3 reference spectra were recorded in urine after the abovementioned workup and analysis. They were confirmed by comparison with the corresponding LC-HR-MS/MS spectra.
LC-HR-MS/MS SUSA
According to Helfer et al. (manuscript submitted), the same LC-HR-MS/MS apparatus was used as for the identification of phase I and II metabolites with gradient elution on a TF Accucore PhenylHexyl column (100×2.1 mm, 2.6 μm). The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1 %, v/v) (pH 3, eluent A) and ammonium formate solution with acetonitrile/methanol (50:50, v/v) containing formic acid (0.1 %, v/v) and water (1 %, v/v) (eluent B). The flow rate was set to 500 μL/min for 10 min and 800 μL/min from 10 to 13.5 min, and the gradient was programmed as follows: 0-1.0 min 1 % B, 1-10 min to 99 % B, 10-11.5 min hold 99 % B, and 11.5-13.5 min hold 1 % B. The HESI-II source conditions were as described above, but with a scan range of m/z 130-1000.
For DDA, high-energy collisional dissociation (HCD) experiments were performed on the five most intense precursor ions selected from FS using DDA (loop count 5). The five most intense precursor ions were transferred to an exclusion list for 8 s defined by the term dynamic exclusion. The remaining settings for DDA mode were as follows: resolution, 17,500; microscans 1, AGC target, 2e5; maximum IT, 250 ms; isolation window, 1.0m/z, HCD with stepped NCE, 17.5, 35, and 52.5 %, spectrum data type, profile, and underfill ratio, 0.5 %.
For identification (I), the accurate precursor ion must be detectable and the underlying HR-MS/MS spectrum must fit with the reference library spectrum. For detection (D), only the accurate precursor ion must be detectable. This classification was in accordance to that described by Broecker et al. [29] .
Results and discussion HR-MS/MS fragmentation and identification of 25I-NBOMe and its phase I metabolites Thirty-seven phase I metabolites could be identified. Therefore, besides the MS 2 spectra of 25I-NBOMe, only those representing typical pathways are depicted in Fig. 1 and discussed in detail here. A list of all phase I metabolites is given in Table 1 . The precursor masses (PM) are given with t h e c a l c u l a t e d e x a c t m a s s e s . T h e 4 -i o d o -2 , 5 -dimethoxyphenethylamine partial structure of the parent compound will be referred as 2C part in the following pages. Fragmentation patterns will be discussed of representatives for each metabolic reactions leading to different fragmentation. 25I-NBOMe (1 in Fig. 1 and Table 1 ; PM at m/z 428.0717, M+H) showed a fragmentation pattern, characteristic also for most of the detected metabolites. The most abundant fragment ion (FI) in MS 2 at m/z 121.0653 represented the cleavage of the methoxybenzyl moiety, followed by the loss of the methoxy group (−30.0105 u) producing the tropylium ion at m/z 91.0548. The FI representing the 2C part showed a low abundance of less than 3 % (inserts of the corresponding spectra in Fig. 1 (Fig. 2) . This rearrangement might be explained by an intramolecular electrophilic attack of the benzyl carbon at position 3, 4, or 6 of the 2C ring system, which was activated by the +M effects of the two methoxy groups and the iodine atom and by the+I effect of the alkyl chain. After elimination of HI and NH=CH 2 this led to the FI at m/z 272.1407 (C 17 H 20 O 3 ).
The MS 2 spectra of the N-demethoxybenzyl metabolite (2C-I, 5, PM at m/z 308.0148, M+H) showed a most abundant FI at m/z 290.9882 representing a shift of ammonia (−17.0266 u). As described above, a loss of a methyl radical (−15.0235 u) formed the FI at m/z 275.9647. In the parent compound spectrum, the same fragments were found without the postulated rearrangement reaction. This metabolite could be further confirmed by comparison with reference material.
N-Demethoxybenzylation in combination with O-demethylation led to two isomers of N-demethoxybenzyl-O-demethyl 25I-NBOMe (2 and 3, PM at m/z 293.9991, M+H). Both showed more or less the same fragmentation pattern (m/z 261.9491 and 276.9726) and an exact prediction, which methoxy group was demethylated, cannot be done. This was marked by a tilde bond in the structures (Figs. 1, 2, 3 , and 4). The fragmentation corresponds to the N-demethoxybenzyl metabolite (5) with a loss of one methyl group (−15.0235 u).
The spectra of O-demethyl metabolites (12 and 14) showed a PM at m/z 414.0561 (M+H) with the elemental composition In contrast to the parent compound, the 2C part showed a FI at m/z 308.0148 indicating a primary amine (as described for the N-demethoxybenzyl metabolite, 5) and not an iminium ion. The following fragmentation patterns were similar to those of the parent compound. The FIs of the 2C part were the same as already described for the Ndemethoxybenzyl metabolite (5). The relative abundance of the 2C FIs was much higher than those seen for the parent compound spectra, which might be explained by a hydrogen bond between the resulting hydroxy group of the methoxybenzyl moiety and the nitrogen atom of the 2C part.
This hydrogen bond might stabilize the molecule explaining why this metabolite did not show any FIs corresponding to the already described rearrangement reaction. Furthermore, this hydrogen bond led to another fragment of the 2C part compared to the non-O-demethylated methoxybenzyl moiety. Instead of the resulting iminium ion (1, m/z 305.9991), a primary amine was formed (m/z 308.0148). This fragmentation pattern could be seen for all metabolites with an O-demethylation at the methoxybenzyl moiety. Hydroxylation took place at different positions (32, 34, and 35; PM at m/z 444.0666, M+H). Isomer 1 (32) showed the fragments of the unchanged methoxybenzyl moiety (m/z 91.0548 and 121.0653) indicating hydroxylation at the 2C part (m/z 306.9831). As no fragments for loss of water were observed, hydroxylation at the aryl ring system could be assumed. Isomer 4 (35) did also form FI at m/z 306.9831, but the FI at m/z 426.0561 representing loss of water (−18.0100 u) indicated hydroxylation at the alkyl chain at an unknown position. Metabolic and/or artificial dehydration led to dehydro 25I-NBOMe (22, PM at m/z 426.0561, M+H; spectrum not shown). The most abundant FIs at m/z 91.0548 and 121.0653 represented the unchanged methoxybenzyl moiety, so the double bond might be located in the 2C part. The position of the double bond might be between the alpha carbon and the nitrogen forming an imine (25I-NBOMe imine analog [5] ). The FIs of the 2C part were different. The FI at m/z 303.9835 representing the 2C nitrilium ion resulted from the benzyl cleavage. In contrast to the compound spectra, this 
HR-MS/MS fragmentation and identification of the phase II metabolites
Thirty phase II metabolites could be identified and selected spectra representing the various pathways are depicted in Fig. 3 . A list of all phase II metabolites is given in Table 2 . All glucuronides eliminated glucuronic acid (−176.0321 u) and all sulfates sulfuric acid (−79.9568 u). For example, the glucuronidated O-demethyl metabolite (58, PM at m/z 590.0882, M+H) eliminated glucuronic acid and, thus, the rest of the spectrum corresponded to that of the O-demethyl metabolite (14, Fig. 1 ). Further fragments were formed of partial structures containing the glucuronic or sulfuric acid rests. These allowed elucidation at which part of the molecule conjugation took place. As already described for 2C-I [17] , the two Ndemethoxybenzyl-O-demethyl metabolites (2 and 3) were conjugated with an acetyl group forming two isomers of Ndemethoxybenzyl-O-demethyl-N-acetyl-25I-NBOMe (39 and 40, PM at m/z 336.0091 M+H). In the following, only isomer 1 (39) will be discussed. This conjugation reaction could be catalyzed by the N-acetyl-transferase (NAT) [30] . The fragmentation pattern was similar to that of the unacetylated metabolites, but FI at m/z 209.1052 resulted from a loss of iodine as a radical and FI at m/z 336.0091 represented the N-acetylated 2C part with iodine.
O,O-bis-demethylation at the 2C part (7) led to hydroquinone, which could be conjugated with glutathione (GSH) by the glutathione-S-transferase [31] . The corresponding degradation products of GSH [31] Another conjugation formed three different metabolites. In the following, only one metabolite will be discussed in detail due to similar fragmentation characteristics. The bis-hydroxylation at the methoxybenzyl moiety (37 and 38) could form a catechol structure (vicinal bis-hydroxylation). These metabolites could be a substrate for the catechol-O-methyl-transferase (COMT). Products of this conjugation could be found. In detail, the bis-hydroxy-O-methyl metabolite (46, PM at m/z 474.0772, M+H) showed the FI at m/z 167.0708 resulted from a shift of the FI at m/z 153.0552 by loss of one methyl group (+14.0156 u) representing the product of the COMT reaction. In addition, the FIs at m/z 290.9882 and 308.0148 represented the unchanged 2C part. The PM at m/z 474.0772 could not be found in the MS 2 spectra (marked with brackets in Fig. 3) . The other two metabolites formed by the COMT were the O,O-bis-demethyl-bis-hydroxy-O-methyl metabolite (42, PM at 446.0459, M+H) and the O-demethyl-bis-hydroxy-O-methyl metabolite (43, PM at m/z 460.0616, M+H, Table. 2). 
Proposed metabolic pathways
According to the metabolites identified in rat and human urine after cleavage of conjugates (Table 1) , the following metabolic pathways, depicted in Fig. 4 , could be proposed: monodemethylation (12, 13, and 14), bis-demethylation (7, 8, and 9), tris-demethylation (6) of the methoxy groups, mono-and bis-hydroxylation (32-36; 38), N-demethoxybenzylation (5), and combinations of mono-hydroxylation with monodemethylation (25) (26) (27) (28) (29) (30) and bis-demethylation (15-21) as well as bis-hydroxylation with mono-demethylation (37) and Ndemethoxybenzylation with mono-demethylation (2 and 3) followed by oxidative deamination and oxidation to the corresponding carboxylic acid (4) .
In summary, O-demethylation seemed to be the main metabolic pathway and N-demethoxybenzylation only a minor one in humans and rats. However, the relative abundance of the different metabolites varied between the species, but it should also be kept in mind that the rat urines were pooled over 24 h and the human urine was collected at an unknown time after administration of an unknown dose. Finally, the relation of the metabolites may vary over the time of excretion. A further limitation is that the rough estimation of relative abundances was based on the assumption that all compounds would show similar peak areas in the applied LC-MS system if present in the same concentration.
The following phase II metabolites could be proposed for humans and/or rats as given in Fig. 4 and in Table 2 : glucuronidation (G) and/or sulfation (S) of the O-demethyl metabolites (56G-58G, and 50S), of the O,O-bis-demethyl metabolites (53G-55G and 47S-49S), of O,O,O-trisdemethyl metabolite (52G, 44S, and 45S), of the Odemethyl-hydroxy metabolites (63G-67G), of the O,Obis-demethyl-hydroxy metabolites (59G-62G), and of the hydroxy metabolites (68G and 69G). Glutathione conjugation could be proposed for the O,O-bis-demethyl metabolite isomer 1 (41GSH and 51GSH), N-acetylation for the N-demethoxybenzyl-O-demethyl metabolites (39 AC and 40 AC), and O-methylation for the bis-hydroxy metabolite (46ME), the O-demethyl-bis-hydroxy metabolite (43ME), and the O,O-bis-demethyl-bis-hydroxy-O-methyl metabolite (42ME).
In summary, all phase II pathways could be proposed for both species with the exception of the N-acetylation, which Table 2 List of all phase II metabolites detected in human (H) or rat (R) urine together with the masses of their precursor mass (PM) recorded in MS 1 , the corresponding characteristic fragment ions (FI) in MS 2 , the calculated exact masses, the corresponding elemental composition, the deviation of the measured from the calculated masses, given as errors in ppm, and the retention times (RT) in min. was observed only in rats after the high dose. Again, the relative abundance also of the different conjugates varied between the species, but this was only a rough estimation as already discussed above.
CYP initial screening
For identification of the CPYs catalyzing the initial metabolic steps, the ten most abundant human hepatic CYPs were Table 3 General involvement of the CYP isoenzymes on the formation of the given 25I-NBOMe metabolites (6) incubated under conditions allowing a statement on the general involvement of a particular CYP enzyme. As summarized in Table 3 , CYP2C9 and CYP2C19 were mainly involved in O-demethylation, CYP1A2 and CYP3A4 in hydroxylation, and CYP3A4 in N-demethoxybenzylation. However, not all isomers detected in urine could be found in these incubations, e.g., only one metabolite O-demethylated at the 2C part.
Toxicological detection of 25I-NBOMe by GC-MS SUSA
Unfortunately, 25I-NBOMe and/or its metabolites could not be detected in rat urine after a common single dose reported in trip reports (https://www.erowid.org) and scaled by dose-byfactor approach from man to rat according to Sharma and McNeill [32] . The authentic human urine sample was also negative. This could be caused by lower sensitivity of GC-MS and most probably by the sample preparation. Preliminary studies showed that the NBOMe's degraded in part during hydrolysis and exposure to oxygen. Only after the high dose, enzymatic cleavage of conjugates, solid-phase extraction, and acetylation according to Welter et al. [25] , small amounts of 25I-NBOMe O-demethyl metabolites could be detected.
Toxicological detection of 25I-NBOMe by LC-MS n SUSA
The LC-MS n approach was able to detect 25I-NBOMe and/or its metabolites in rat urine after the 0.05 or 0.1 mg/kg BW dose as well as in the authentic human urine sample. A list of Fig. 5 Reconstructed ion chromatograms of the given exact masses indicating the identified metabolites in the human urine by LC-HR-MS/MS SUSA (peak numbering according to Tables 1 and 2) the detected metabolites is given in Table 4 . As already mentioned above, the differences of detected analytes in the human and rat urine samples could be caused by different doses and urine collection times.
Toxicological detection of 25I-NBOMe by LC-HR-MS/MS SUSA
In addition, the detectability was also tested by the new LC-HR-MS/MS screening approach (Helfer et al., submitted). As expected, this approach was also able to detect 25I-NBOMe and/or its metabolites in rat urine after the 0.05 or 0.1 mg/kg BW dose as well as in the authentic human urine sample. A list of the identified or detected metabolites in human as well as in rat samples is given in Table 5 . Again, the differences of detected analytes in the human and rat urine samples could be caused by different doses and urine collection times. Figure 5 shows reconstituted ion chromatograms of the human urine sample indicating various metabolites, which could be identified according to definition given above. In this sample, the parent drug could only be detected in contrast to the rat urine samples after the 0.1 mg/kg BW dose.
Conclusion
25I-NBOMe was extensively metabolized with O-demethylation, O,O-bis-demethylation, and hydroxylations as predominant pathways. Several CYP isoenzymes were involved in formation of the main metabolites. An intake could be detected mainly via its metabolites by low and high resolution LC-MS SUSAs.
